Atlas Trials

G1 Therapeutics, Inc.

16 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch G1 Therapeutics, Inc.

RecordFirmDate
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer (NCT05112536)G1 Therapeutics, Inc.2022-03-03
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer (NCT05113966)G1 Therapeutics, Inc.2021-12-08
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab (NCT04887831)G1 Therapeutics, Inc.2021-06-04
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) (NCT04799249)G1 Therapeutics, Inc.2021-05-14
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) (NCT04863248)G1 Therapeutics, Inc.2021-04-30
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (NCT04607668)G1 Therapeutics, Inc.2021-01-06
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer (NCT03455270)G1 Therapeutics, Inc.2018-05-09
G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer (NCT03455829)G1 Therapeutics, Inc.2018-03-29

Track G1 Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.